Relyvrio Falls Short of Primary Endpoint in Phase III PHOENIX Trial in Patients with ALS

Relyvrio did not significantly alter amyotrophic lateral sclerosis disease progression as measured by the ALSFRS-R total score at Week 48 compared to placebo.